Riken Vitamin Co., Ltd. (4526) AI Stock Analysis

• Market Cap: ¥68.32B
• Dividend Yield: 3.63%
• Average Volume (3M): 91.61K
• Price to Earnings (P/E): 8.5
• Beta (1Y): 0.47
• Revenue Growth: 1.78%
• EPS Growth: 19.50%
• Country: JP
• Employees: 1,857
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): 87.72
• Shares Outstanding: 30,705,100
• 10 Day Avg. Volume: 57,120
• 30 Day Avg. Volume: 91,606
• PEG Ratio: 0.50
• Price to Book (P/B): 0.93
• Price to Sales (P/S): 0.77
• P/FCF Ratio: 23.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 270.53
• Revenue Forecast (FY): ¥98.40B

• Rating: 82 Outperform
• Price Target: ¥3,548.00 ▲(19.58% Upside)
• Action: Reiterated Date: 07/25/25
• Date: Action: Reiterated 07/25/25

Riken Vitamin Co., Ltd. achieves a robust overall stock score due to a combination of strong financial performance, attractive valuation, and positive technical indicators. The company's financial health, characterized by solid profitability and low leverage, is complemented by an undervalued stock price and a strong upward price trend. The absence of recent earnings call data or notable corporate events did not impact the score calculation.

Positive Factors

Balance sheet strength

Riken Vitamin's very low leverage and high equity ratio provide durable financial flexibility. A 0.13 debt/equity and solid ROE support capital allocation for R&D, product development, dividends or opportunistic M&A while reducing refinancing and solvency risk in downturns.

Cash generation capability

High cash conversion (OCF/net income 0.84) indicates the business converts profit into cash reliably, supporting reinvestment and shareholder returns. Even with a recent decline, positive free cash flow provides a structural source to fund operations and product investments.

Healthy profit margins

Sustained gross and operating margins reflect durable cost control and pricing power in ingredient and processed-food segments. Strong margins help absorb commodity cost swings and support reinvestment and long-term profitability across product mixes.

Negative Factors

Falling operating cash flow

A year-over-year drop in operating cash flow can signal weakening cash conversion from core operations or working-capital strain. That trend, if persistent, will reduce internal funding for capex, product development or dividends and heighten reliance on external financing.

Shrinking asset/cash base

A reduction in total assets and cash balances diminishes the company’s financial buffer and capacity to scale operations or pursue strategic investments. Over several quarters this can constrain growth initiatives and reduce ability to absorb demand shocks.

Recent revenue weakness

Negative top-line growth in the latest period weakens operating leverage and could reflect softer demand, product mix shifts, or competitive pressure in ingredients and processed foods. Continued revenue declines would challenge margin sustainability and long-term expansion plans.

Riken Vitamin Co., Ltd. Business Overview & Revenue Model

Company Description

Riken Vitamin Co., Ltd. engages in the food ingredient, food application, health care, and chemical businesses in Japan. It offers food emulsifies for use in bread, cake, whipped topping, coffee cream, margarine, tofu, jam, marmalade, ice cream, cocoa, chocolate, noodle, and mashed potato applications; and distilled diglycerine ester, a substance that diglycerine reacts with fatty acids. The company also provides natural tocopherol for retarding oxidation to keep food products fresh; natural food colors; flavors for seasoning, sea food, chicken, and beef products; wakame seaweed that is used in wakame soup, seafood salads, instant noodles, and cup noodle ingredients; and stabilizers and emulsifiers system for frozen desserts and dairy products, as well as bakery emulsifiers and bread improvers, and cake improving agents and emulsifiers. In addition, it offers chemical improving agents, such as glycerol, polyglycerol, sorbitan, propylene glycol, and specialty esters, as well as other agents; and vitamins. The company was formerly known as Riken Vitamin Oil Co., Ltd. and changed its name to Riken Vitamin Co., Ltd. in 1980. Riken Vitamin Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Riken Vitamin Co., Ltd. generates revenue through multiple streams, primarily by selling its core products, including vitamins and amino acids, to various industries such as pharmaceuticals, food, and dietary supplements. The company capitalizes on its strong research and development capabilities to create specialized products that meet specific health and nutrition needs, allowing it to command premium pricing. Additionally, Riken Vitamin engages in strategic partnerships with other companies in the health and wellness sectors, enhancing its market reach and distribution capabilities. The company also benefits from licensing agreements and collaborations that further diversify its revenue sources. Its established reputation for quality and innovation helps to maintain a loyal customer base, contributing to sustained earnings.

Riken Vitamin Co., Ltd. Financial Statement Overview

Summary

Riken Vitamin Co., Ltd. showcases strong financial performance with consistent revenue growth, impressive profitability margins, and a solid balance sheet. The company maintains a low debt-to-equity ratio and effective use of shareholders' capital, despite a decrease in operating cash flow.

Income Statement

Riken Vitamin Co., Ltd. has demonstrated a strong financial performance in the income statement with consistent revenue growth, notably a 4.48% increase in the latest year. The gross profit margin is solid at 32.70%, showing effective cost management. The net profit margin stands at 9.82%, indicating healthy profitability. Both EBIT and EBITDA margins have shown stability, with figures of 9.13% and 16.77% respectively, reflecting efficient core operations. However, the reduction in EBIT from the previous year indicates some pressure on operating efficiencies.

Balance Sheet

The company's balance sheet is strong, characterized by a low debt-to-equity ratio of 0.13, indicating conservative leverage. The return on equity is impressive at 11.86%, suggesting effective use of shareholders' capital. The equity ratio of 70.03% demonstrates a robust capital structure with a significant portion of assets financed by equity. The reduction in total liabilities over the years further enhances financial stability. However, a decrease in total assets and cash equivalents from the previous year needs monitoring.

Cash Flow

Riken Vitamin Co., Ltd. has shown a positive cash flow position with a substantial operating cash flow to net income ratio of 0.84, indicating strong cash-generating capabilities. The free cash flow to net income ratio is 0.33, reflecting ample free cash flow for reinvestment despite a decline in free cash flow from the prior year. While this suggests effective cash management, the decrease in operating cash flow over the past year is a point of concern and should be addressed.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	95.21B	95.58B	91.48B	88.75B	79.23B	77.72B
Gross Profit	30.97B	31.27B	29.89B	27.24B	25.57B	22.01B
EBITDA	15.63B	16.04B	15.35B	11.71B	24.23B	4.61B
Net Income	8.84B	9.39B	8.76B	6.41B	21.58B	-1.62B
Balance Sheet
Total Assets	112.78B	113.00B	118.78B	105.22B	102.66B	106.53B
Cash, Cash Equivalents and Short-Term Investments	20.05B	22.30B	23.38B	19.16B	17.30B	19.23B
Total Debt	10.13B	9.91B	16.05B	14.56B	17.53B	24.37B
Total Liabilities	33.72B	33.80B	42.13B	33.85B	36.12B	59.86B
Stockholders Equity	79.02B	79.16B	76.61B	71.34B	66.52B	46.16B
Cash Flow
Free Cash Flow	0.00	3.12B	7.42B	5.67B	3.44B	3.85B
Operating Cash Flow	0.00	7.89B	10.45B	7.83B	6.82B	7.63B
Investing Cash Flow	0.00	353.00M	-554.00M	-2.03B	-3.66B	-2.29B
Financing Cash Flow	0.00	-9.96B	-7.08B	-4.58B	-7.57B	-180.00M

Riken Vitamin Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2967.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4526, the sentiment is Negative. The current price of 2967 is below the 20-day moving average (MA) of 3086.90, below the 50-day MA of 3073.78, and above the 200-day MA of 2861.07, indicating a neutral trend. The MACD of -25.55 indicates Positive momentum. The RSI at 42.10 is Neutral, neither overbought nor oversold. The STOCH value of 31.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4526.

Riken Vitamin Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4526	82 Outperform	¥68.32B	8.46	―	3.63%	1.78%	19.50%
2927	64 Neutral	¥12.75B	5.91	―	3.94%	11.47%	29.21%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
2802	61 Neutral	¥4.39T	20.92	9.46%	1.32%	1.99%	-18.79%
2264	59 Neutral	¥425.52B	10.37	―	2.42%	2.33%	-8.76%
3139	59 Neutral	¥36.79B	8.05	―	3.84%	6.49%	31.81%
2607	57 Neutral	¥297.94B	10.01	―	1.45%	20.02%	―

Riken Vitamin Co., Ltd. Corporate Events

Riken Vitamin Advances Toward Completion of ¥2 Billion Share Buyback Program

Riken Vitamin Co., Ltd. has reported progress on its ongoing share repurchase program, acquiring 57,300 shares of its common stock on the Tokyo Stock Exchange between February 1 and February 28, 2026, at a total cost of 179,067,993 yen. This buyback is part of a broader board-authorized program, under which the company has cumulatively repurchased 643,200 shares for 1,843,819,320 yen as of February 28, 2026, moving closer to its upper limit and signaling continued capital return efforts that may support shareholder value and share price stability.

The current buyback operates within a resolution approved on April 30, 2025, allowing the acquisition of up to 1,000,000 shares and 2 billion yen in total, via market purchases through March 24, 2026. By steadily executing this plan, Riken Vitamin is utilizing its balance sheet to adjust capital structure and demonstrate confidence in its long-term prospects, which can be viewed positively by investors focused on capital efficiency and equity returns.

The most recent analyst rating on (JP:4526) stock is a Buy with a Yen3550.00 price target. To see the full list of analyst forecasts on Riken Vitamin Co., Ltd. stock, see the JP:4526 Stock Forecast page.

Riken Vitamin Profit Hit by Overseas Slump and Asbestos Costs, Net Income Buoyed by Share Sales

Riken Vitamin Co., Ltd. reported that consolidated net sales edged down year on year as growth in domestic food and chemical operations was outpaced by a sharp decline in overseas sales, which swung to an operating loss amid weaker gross profit and higher labor costs. Group operating profit fell, further hit by a non-cash increase in asset retirement obligations related to asbestos removal, although price revisions and cost controls partly cushioned domestic margins.

Despite lower operating profit, net income rose on the back of gains from selling investment securities linked to a reduction in cross-shareholdings, underscoring a shift toward a more efficient capital structure. Segment data show resilient demand for processed food ingredients and steady commercial food and chemical sales, but the deterioration in overseas performance and the asbestos-related cost revision highlight structural challenges that could weigh on profitability and require continued strategic adjustments in the company’s international and legacy-asset portfolios.

The most recent analyst rating on (JP:4526) stock is a Buy with a Yen3581.00 price target. To see the full list of analyst forecasts on Riken Vitamin Co., Ltd. stock, see the JP:4526 Stock Forecast page.

Riken Vitamin Slashes Full-Year Profit Outlook on Overseas Weakness and Asbestos Costs

Riken Vitamin Co., Ltd. has lowered its consolidated full-year forecast for the fiscal year ending March 31, 2026, cutting projected net sales from ¥100 billion to ¥96 billion and trimming expected profit attributable to owners of parent from ¥8.2 billion to ¥6.5 billion. Earnings per share are now forecast at ¥219.84, down from ¥274.49 and well below the previous year’s ¥310.08, signaling a notable deterioration in expected profitability.

The downward revision is driven by sluggish consumer demand in China and intensified price competition in Europe and Southeast Asia, which are weighing heavily on the company’s Overseas business. Additionally, a revised estimate of asset retirement obligations tied to asbestos removal costs is set to depress operating profit in the Domestic Food business, although Riken Vitamin is maintaining its year-end dividend forecast despite the weaker earnings outlook.

The most recent analyst rating on (JP:4526) stock is a Buy with a Yen3581.00 price target. To see the full list of analyst forecasts on Riken Vitamin Co., Ltd. stock, see the JP:4526 Stock Forecast page.

Riken Vitamin Cuts Profit Outlook Despite Solid Balance Sheet and Higher Dividends

Riken Vitamin reported nine‑month consolidated net sales to December 31, 2025 of ¥72.5 billion, edging down 0.5% year on year, while operating profit fell 24.2% to ¥5.7 billion and ordinary profit dropped 22.3%. Profit attributable to owners of parent rose 2.0% to ¥5.9 billion, lifting earnings per share to ¥200.75, and comprehensive income increased 19.5%, reflecting stronger overall profitability despite margin pressure.

The company’s financial position remained sound, with total assets rising to ¥116.7 billion and an equity ratio of 70.2%, while it continued shareholder returns, paying a higher interim dividend and maintaining a full‑year dividend forecast of ¥110 per share. Riken Vitamin revised its full‑year earnings outlook, still projecting 4.0% sales growth to ¥96.0 billion but expecting operating profit to decline 28.9% and net profit 30.8%, signaling a more challenging profit environment even as balance sheet strength and dividend policy support investor confidence.

The most recent analyst rating on (JP:4526) stock is a Buy with a Yen3581.00 price target. To see the full list of analyst forecasts on Riken Vitamin Co., Ltd. stock, see the JP:4526 Stock Forecast page.

Riken Vitamin Reports Progress on Ongoing Share Buyback Program

Riken Vitamin Co., Ltd., a Tokyo Stock Exchange Prime Market-listed food ingredients and vitamin producer, continues to actively manage its capital structure through share repurchases authorized by its board in April 2025. During the period from January 1 to January 31, 2026, the company bought back 62,200 shares of its common stock on the Tokyo Stock Exchange at a total cost of approximately 190 million yen, bringing cumulative repurchases under the current program to 585,900 shares and about 1.66 billion yen. This leaves headroom under the existing authorization, which permits up to 1 million shares and 2 billion yen in total, indicating ongoing potential for further buybacks that may support shareholder returns and bolster metrics such as earnings per share and return on equity.

The most recent analyst rating on (JP:4526) stock is a Buy with a Yen3555.00 price target. To see the full list of analyst forecasts on Riken Vitamin Co., Ltd. stock, see the JP:4526 Stock Forecast page.

Riken Vitamin Updates Progress on Ongoing Share Buyback Program

Riken Vitamin Co., Ltd. has reported the latest progress of its share buyback program authorized by its board on April 30, 2025, under which it is repurchasing common stock on the Tokyo Stock Exchange. During the period from December 1 to December 31, 2025, the company acquired 61,600 shares for a total of 178,019,591 yen, bringing cumulative repurchases as of December 31, 2025, to 523,700 shares at a total cost of 1,474,531,634 yen, against an authorized ceiling of 1,000,000 shares or 2 billion yen to be executed by March 24, 2026, indicating ongoing efforts to enhance capital efficiency and shareholder returns through treasury stock acquisition.

The most recent analyst rating on (JP:4526) stock is a Buy with a Yen3244.00 price target. To see the full list of analyst forecasts on Riken Vitamin Co., Ltd. stock, see the JP:4526 Stock Forecast page.